Literature DB >> 28936397

Targeted attack: mechanisms by which ovarian cancers suppress the immune system.

Irina V Tiper1, Tonya J Webb1.   

Abstract

Entities:  

Year:  2016        PMID: 28936397      PMCID: PMC5604241          DOI: 10.21037/tcr.2016.11.62

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  9 in total

1.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Authors:  A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller
Journal:  Int J Gynaecol Obstet       Date:  2006-11       Impact factor: 3.561

Review 2.  Immunotherapy opportunities in ovarian cancer.

Authors:  Christina S Chu; Sarah H Kim; Carl H June; George Coukos
Journal:  Expert Rev Anticancer Ther       Date:  2008-02       Impact factor: 4.512

3.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

4.  Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Authors:  Aristotelis Bamias; Vasiliki Koutsoukou; Evangelos Terpos; Marinos L Tsiatas; Christina Liakos; Ourania Tsitsilonis; Alexandros Rodolakis; Zannis Voulgaris; G Vlahos; Theocharis Papageorgiou; G Papatheodoridis; A Archimandritis; A Antsaklis; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

5.  Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.

Authors:  C Rudlowski; A-K Pickart; C Fuhljahn; T Friepoertner; B Schlehe; S Biesterfeld; W Schroeder
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

Review 6.  Ovarian cancer detection and treatment: current situation and future prospects.

Authors:  Marylène Argento; Pascale Hoffman; Anne-Sophie Gauchez
Journal:  Anticancer Res       Date:  2008 Sep-Oct       Impact factor: 2.480

Review 7.  FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.

Authors:  Beyhan Ataseven; Luis M Chiva; Philipp Harter; Antonio Gonzalez-Martin; Andreas du Bois
Journal:  Gynecol Oncol       Date:  2016-06-19       Impact factor: 5.482

8.  VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Authors:  Irina V Tiper; Sarah M Temkin; Sarah Spiegel; Simeon E Goldblum; Robert L Giuntoli; Mathias Oelke; Jonathan P Schneck; Tonya J Webb
Journal:  Clin Cancer Res       Date:  2016-04-13       Impact factor: 12.531

9.  VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2.

Authors:  N G Gavalas; M Tsiatas; O Tsitsilonis; E Politi; K Ioannou; A C Ziogas; A Rodolakis; G Vlahos; N Thomakos; D Haidopoulos; E Terpos; A Antsaklis; M A Dimopoulos; A Bamias
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

  9 in total
  1 in total

Review 1.  Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?

Authors:  Elena García-Martínez; Andres Redondo; Josep Maria Piulats; Analía Rodríguez; Antonio Casado
Journal:  Angiogenesis       Date:  2020-07-20       Impact factor: 9.596

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.